Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemant Surgical IndustriesBOM:543916 -0.97%80 Return-on-Tangible-Equity is 19.53% as of Mar. 2026, which is 10% below its 10-year median of 21.59. GuruFocus rates BOM:543916 with a GF Score™ of 80/100 and a GF Value™ of ₹335.02 (Fairly Valued). The stock has 3 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Hemant Surgical Industries ranks better than 78.63% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hemant Surgical Industries's annualized net income for the quarter that ended in Mar. 2026 was ₹255 Mil. Hemant Surgical Industries's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹1,304 Mil. Therefore, Hemant Surgical Industries's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 19.53%.
The historical rank and industry rank for Hemant Surgical Industries's Return-on-Tangible-Equity or its related term are showing as below:
BOM:543916'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.71 Med: 21.59 Max: 41.84
Current: 16.85
During the past 6 years, Hemant Surgical Industries's highest Return-on-Tangible-Equity was 41.84%. The lowest was 11.71%. And the median was 21.59%.
BOM:543916's Return-on-Tangible-Equity is ranked better than 78.63% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.15
vs BOM:543916: 16.85
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hemant Surgical Industries Return-on-Tangible-Equity Related Terms
Hemant Surgical Industries Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543916 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Hemant Surgical Industries's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemant Surgical Industries Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hemant Surgical Industries's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hemant Surgical Industries's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.53% mean?
Hemant Surgical Industries (BOM:543916) has a Return-on-Tangible-Equity of 19.53% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hemant Surgical Industries and its competitors. This is 10% below median its historical median of 21.59. Over the past decade, Hemant Surgical Industries' Return-on-Tangible-Equity has ranged from 11.71 to 41.84. According to the industry distribution chart, Hemant Surgical Industries ranks #162 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 21.4%.
Is Hemant Surgical Industries' Return-on-Tangible-Equity too high?
Hemant Surgical Industries' current Return-on-Tangible-Equity of 19.53% is 10% below median its 10-year median of 21.59. Over the past 10 years, this metric has ranged from a low of 11.71 to a high of 41.84. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.15. Hemant Surgical Industries' value of 19.53% is 370.6% above this industry median. Based on the distribution chart, Hemant Surgical Industries ranks #162 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hemant Surgical Industries has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hemant Surgical Industries' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hemant Surgical Industries ranks #162 out of 758 companies for Return-on-Tangible-Equity. This places Hemant Surgical Industries in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.15. Hemant Surgical Industries' value of 19.53% is 370.6% above this benchmark. Historically, Hemant Surgical Industries' own Return-on-Tangible-Equity has ranged from 11.71 to 41.84 over the past decade. While the company's 10-year median is 21.59 vs. the industry median of 4.15, Hemant Surgical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.15, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemant Surgical Industries's current Return-on-Tangible-Equity of 19.53% is 370.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hemant Surgical Industries and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemant Surgical Industries's current Return-on-Tangible-Equity is 19.53%, which is 10% below median its own 10-year median of 21.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemant Surgical Industries stock overvalued right now?
Based on GuruFocus' analysis, Hemant Surgical Industries (BOM:543916) is currently considered Fairly Valued. The stock's GF Value™ is ₹335.02, compared to a current price of ₹356.25 — trading 6.3% above its estimated fair value. The current Return-on-Tangible-Equity is 19.53%, which is 10% below median its 10-year median of 21.59 and 370.6% above the Medical Devices & Instruments industry median of 4.15. Hemant Surgical Industries' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hemant Surgical Industries (BOM:543916), the current Return-on-Tangible-Equity is 19.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hemant Surgical Industries (BOM:543916) Overvalued in 2026?
Based on GuruFocus' analysis, Hemant Surgical Industries stock appears to be overvalued.
The current stock price of ₹356.25 is trading 6.3% above its estimated GF Value™ of ₹335.02.
GuruFocus considers Hemant Surgical Industries to be Fairly Valued.
Key valuation signals for BOM:543916:
Return-on-Tangible-Equity: 19.53% (10% below median its 10-year median of 21.59)
GF Value™: ₹335.02 vs. price of ₹356.25 (6.3% above fair value)
Industry Position: 370.6% above the Medical Devices & Instruments median (#162 of 758)
No single metric tells the full story. See the BOM:543916 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemant Surgical Industries Ltd is engaged in Importing, manufacturing, and marketing quality surgical and Pharmaceutical Products at an economical price. Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease, (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables. Its products include JMS Meditape, JMS Infusion Set, JMS Scalp Vein Set, Ventilators, ECG Machines, and others.
80GF Score
Get the complete analysis for BOM:543916
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543916 has been successfully added to your 
